Search results
Results from the WOW.Com Content Network
Carcinoma in situ (CIS) is a group of abnormal cells. [ 1 ] [ 2 ] While they are a form of neoplasm , [ 3 ] there is disagreement over whether CIS should be classified as cancer . This controversy also depends on the exact CIS in question (e.g., cervical, skin, breast).
Cryogenic electron tomography (cryoET) is an imaging technique used to reconstruct high-resolution (~1–4 nm) three-dimensional volumes of samples, often (but not limited to) biological macromolecules and cells.
In-vivo cryoablation of a tumor, alone, can induce an immunostimulatory, systemic anti-tumor response, resulting in a cancer vaccine—the abscopal effect. [2] Thus, cryoablation of tumors is a way of achieving autologous , in-vivo tumor lysate vaccine and treat metastatic disease.
Papillary carcinomas of the breast (PCB), also termed malignant papillary carcinomas of the breast, are rare forms of the breast cancers. [1] The World Health Organization (2019) classified papillary neoplasms (i.e. benign or cancerous tumors) of the breast into 5 types: intraductal papilloma, papillary ductal carcinoma in situ (PDCIS), encapsulated papillary carcinoma (EPC), solid-papillary ...
Stage 0: carcinoma in situ, abnormal cells growing in their normal place ("in situ" from Latin for "in its place"). Stage 0 can also mean no remaining cancer after preoperative treatment in some cancers (e.g. colorectal cancer). Stage I: cancers are localized to one part of the body. Stage I cancer can be surgically removed if small enough.
Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive cancerous lesion of the breast. [ 1 ] [ 2 ] DCIS is classified as Stage 0. [ 3 ] It rarely produces symptoms or a breast lump that can be felt, typically being detected through screening mammography .
Affordability is becoming a growing challenge for younger generations. Although they're often drawn to vibrant cities for their career opportunities and lifestyle perks, high housing costs make ...
The Raunser lab has contributed to developments in cryoEM image processing and cryoET hardware development. [26] They developed SPHIRE [27] (together with Pawel Penczek), which evolved later into TranSPHIRE. [28] The program offers an easy-to-use and versatile image processing suite for the single particle analysis of protein complexes in CryoEM.